Skip to content

Developing a Predictive Model for Hepatic Encephalopathy After TIPS in Cirrhosis Based on Sarcopenia: A Multicenter Cohort Study

Developing a Predictive Model for Hepatic Encephalopathy After TIPS in Cirrhosis Based on Sarcopenia: A Multicenter Cohort Study

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2500095842
Enrollment
Unknown
Registered
2025-01-14
Start date
2025-02-01
Completion date
Unknown
Last updated
2025-01-27

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Cirrhotic patients undergoing TIPS

Interventions

Case series:No

Sponsors

Xi'an Jiaotong University Second Affiliated Hospital
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to No maximum

Inclusion criteria

Inclusion criteria: 1. Cirrhosis from various etiologies is confirmed through clinical data combined with imaging or liver biopsy. 2. Cirrhotic patients undergo TIPS procedure based on appropriate indications, such as variceal bleeding and refractory ascites. 3.Patients have preoperative abdominal CT imaging available at the treating hospital to assess sarcopenia.

Exclusion criteria

Exclusion criteria: 1. Age under 18 years. 2. Uncertain cirrhosis diagnosis or undergoing TIPS for other reasons, such as Budd-Chiari syndrome or idiopathic portal hypertension. 3. Previously received TIPS, with current procedure performed due to stent occlusion. 4. Poor quality abdominal CT imaging, lack of third lumbar vertebra level imaging, absence of dynamic CT images (e.g., only film available), or preoperative CT performed more than 3 months before surgery. 5. Presence of neurological or psychiatric disorders, or current use of anti-anxiety or antidepressant medications interfering with postoperative HE assessment. 6. Advanced liver cancer exceeding Milan criteria, other systemic malignancies, or severe chronic diseases (e.g., stage 4 or higher chronic kidney disease) impacting patient prognosis. 7. Incomplete or missing clinical data. 8. Loss to follow-up within 3 months. 9. Prospective cohort patients who declined to sign informed consent or requested withdrawal during the study.

Design outcomes

Primary

MeasureTime frame
Sarcopenia;

Secondary

MeasureTime frame
discriminability;Calibration degree;Clinical utility;

Countries

China

Contacts

Public ContactXinxing Tantai

Xi'an Jiaotong University Second Affiliated Hospital

441434801@qq.com+86 29 87679335

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026